Predictive value of growth differentiation factor-15 in patients with myocardial infarction
Open Access
- 28 March 2021
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (2), 4288
- https://doi.org/10.15829/1560-4071-2021-4288
Abstract
Aim. To evaluate the prognostic value of growth differentiation factor-15 (GDF-15) in patients with acute myocardial infarction (MI).Material and methods. The study included 118 patients under the age of 70 with STand non-ST segment elevation myocardial infarction, who, in addition to routine examination, were tested for GDF-15 by enzyme-linked immunosorbent assay in the first 48 hours from the onset. The statistical significance of the differences in quantitative indicators was assessed by the Student’s t-test for a normal distribution and by the nonparametric U Mann-Whitney test for a non-normal distribution, while in qualitative indicators — by Pearson’s chisquared test. Pearson’s correlation coefficient and Spearman’s rank correlation coefficient were used as an indicator of strength of relationship between quantitative indicators.Results. The average GDF-15 level in patients with MI was 2,25±1,0 ng/ml. For 6 months of follow-up, 15,25% of patients were rehospitalized for unstable angina or recurrent myocardial infarction. The GDF-15 level in 82,6% of cases was in the third and fourth quartiles (≥2,07 ng/ml). All patients with recurrent MI had GDF-15 levels in the upper quartile (≥2б73 ng/ml). Patients with GDF-15 levels in the upper quartile had a significantly higher risk of rehospitalization (hazard ratio, 3,3 (95% CI, 1,65-6,76), p2,73 ng/ml, NT-proBNP>1418 pg/ml) had 4,8 times higher risk of rehospitalizations for unstable angina or recurrent myocardial infarction.Conclusion. In patients with MI, the determination of the GDF-15 level has prognostic value and may serve as an additional marker of the risk of recurrent cardiovascular events.This publication has 11 references indexed in Scilit:
- Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillationEuropean Heart Journal, 2020
- Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal playerESC Heart Failure, 2020
- Growth Differentiation Factor 15 as a Biomarker in Cardiovascular DiseaseClinical Chemistry, 2017
- Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarctionEuropean Heart Journal, 2009
- Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarctionEuropean Heart Journal, 2007
- Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non–ST-Elevation Acute Coronary SyndromeJournal of the American College of Cardiology, 2007
- Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary SyndromeJournal of the American College of Cardiology, 2007
- GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein ActivationCirculation Research, 2006
- MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamilyProceedings of the National Academy of Sciences of the United States of America, 1997